Research programme: cannabinoid receptor CB1 antagonists - Bayer
Latest Information Update: 24 Mar 2010
At a glance
- Originator Bayer
- Class Pyridones
- Mechanism of Action Cannabinoid receptor CB1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 21 Mar 2002 Preclinical trials in Obesity in Germany (unspecified route)